In patients with advanced CRC, it is essential to determine extended RAS mutations, the BRAF V600E mutation and the MSI status, which is usually performed via IHC for MLH1, MSH2, MSH6 and PMS2. The determination of extended RAS mutations is mandatory before making therapeutic decisions (I-A). This evidence concerns the gene BRAF and colorectal carcinoma.